Scynexis (SCYX) Share-based Compensation Growth (3y) (2016 - 2026)
Scynexis (SCYX) Share-based Compensation Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 10.06% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 9.14% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 0.43% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -8.13% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | -1.73% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | -8.04% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Scynexis | 62.02 Mn | -52.68 Mn | - | -6.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.24% |
| Mar 31, 2026 | -6.08% |
| Dec 31, 2025 | 14.81% |
| Sep 30, 2025 | -21.59% |
| Jun 30, 2025 | -9.33% |
| Mar 31, 2025 | -3.09% |
| Dec 31, 2024 | 20.55% |
| Sep 30, 2024 | 14.47% |
| Jun 30, 2024 | 14.93% |
| Mar 31, 2024 | 20.79% |
| Dec 31, 2023 | 43.48% |
| Sep 30, 2023 | 14.57% |
| Jun 30, 2023 | 19.42% |
| Mar 31, 2023 | 112.45% |
| Dec 31, 2022 | 33.75% |
| Sep 30, 2022 | 37.37% |
| Jun 30, 2022 | 35.11% |
| Mar 31, 2022 | 22.30% |
| Sep 30, 2021 | 9.42% |
| Jun 30, 2021 | 2.23% |